A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells

Cancer Research

Volumn 61, Issue 16, 2001, Pages 6170-6177

  Lane, Maureen E ^a   Yu, Bo ^a   Pestell, Richard G ^a   Wadler, Scott ^a   Rice, Audie ^b   Lipson, Kenneth E ^b   Liang, Chris ^b   Sun, Li ^b   Tang, Cho ^b   McMahon, Gerald ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b SUGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (3H IMIDAZOL 4 YL)METHYLIDENE] 5 METHOXY 1,3 DIHYDROINDOL 2 ONE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; SU 9516; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CDC2-CDC28 KINASES; CELL DIVISION; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; GROWTH INHIBITORS; HUMANS; IMIDAZOLES; INDOLES; MOLECULAR CONFORMATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0035881591     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Cancer cell cycles
2. Unrestricted cell cycling and cancer
3. The retinoblastoma protein and cell cycle control
4. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex
5. Cell cycle-regulated transcription in mammalian cells
6. The regulation of E2F by pRB-family proteins
7. Cyclins and cyclin-dependent kinases: A biochemical view
8. Cyclins and cyclin-dependent kinases: Theme and variations
9. Differential regulation of E2F transactivation by cyclin/cdk2 complexes
10. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase
11. Expression of transcription factor E2F1 induces quiescent cells to enter S phase
12. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis
13. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis
14. p53 and E2F-1 cooperate to mediate apoptosis
15. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation
16. Amplification of cyclin genes in colorectal carcinomas
17. Concurrent amplification of cyclin E and cdk2 genes in colorectal carcinomas
18. Analysis of cyclin E and cdk2 in ovarian cancer: Gene amplification and RNA overexpression
19. Different expression patterns of cyclins A, D1 and E in human colorectal cancer
20. Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p300/CBP co-activators
21. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
22. Cip/Kip cyclin-dependent kinase inhibitors: Brakes of the cell cycle engine during development
23. Cell-cycle inhibitors: Three families united by a common cause
24. The INK4 family of cell cycle inhibitors in cancer
25. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein
26. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
27. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol
28. Structural basis for specificity and potency of a flavonoid inhibitor of human cdk2, a cell cycle kinase
29. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants
30. Activation of human cyclin-dependent kinases in vitro
31. New colorimetric cytotoxicity assay for anticancer-drug screening
32. Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis
33. Mechanisms of cyclin-dependent kinase inactivation by progestins
34. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
35. ATP-site directed inhibitors of cyclin-dependent kinases
36. Small-molecule inhibitors of cyclin-dependent kinases: Molecular tools and potential therapeutics
37. cdk inhibition and cancer therapy
38. Cyclin-dependent kinase inhibitors: Novel anticancer agents
39. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms
40. 1 arrest with inhibition of cyclin-dependent kinase (cdk) 2 and cdk4 in human breast carcinoma cells
41. Inhibition of cyclin-dependent kinases by purine analogues: Crystal structure of human cdk2 complexed with Roscovitine
42. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
43. Multiple modes of ligand recognition: Crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine
44. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes
45. Transcription factor E2F and cyclin E-Cdk2 complex cooperate to induce chromosomal DNA replication in Xenopus oocytes
46. 1 cyclin-dependent kinase activity
47. Cyclin E-induced, S. Phase without activation of the pRb/E2F pathway
48. Cdk2-dependent and -independent pathways in E2F-mediated S phase induction
49. 1 cyclin-dependent kinase activity in the induction of S phase
50. Reduced cyclin D1 expression in the cerebella of nutritionally deprived rats correlates with developmental delay and decreased cellular DNA synthesis
51. Cyclin D1 is required for S phase traversal in bovine tracheal myocytes
52. 1 cyclins in senescent human diploid fibroblasts: Accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes
53. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from pI6cdkN2/INK4A
54. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription
55. A role for Cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle
56. The cyclin dependent kinase 2 inhibitor, SU9516, promotes accumulation of the pRb/E2F complex in human colon carcinoma cells
57. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint
58. Cyclin A/cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation
59. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
60. E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction
61. Induction of DNA synthesis and apoptosis are separable functions of E2F-1
62. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles
63. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins
64. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase
65. Xenopus Cdc45-dependent loading of DNA polymerase α onto chromatin under the control of S-phase Cdk
66. Expression of NPAT, a novel substrate of cyclin E-cdk2, promotes S-phase entry